Lometrexol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lometrexol
Accession Number
DB12769
Type
Small Molecule
Groups
Investigational
Description

Lometrexol has been used in trials studying the treatment of Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, and Unspecified Adult Solid Tumor, Protocol Specific.

Structure
Thumb
Synonyms
Not Available
External IDs
LY264618
Product Ingredients
IngredientUNIICASInChI Key
Lometrexol sodiumUS81N1145TNot AvailableSVJSWELRJWVPQD-KJWOGLQMSA-L
Categories
UNII
6P3AVY8A7Q
CAS number
106400-81-1
Weight
Average: 443.4531
Monoisotopic: 443.180483557
Chemical Formula
C21H25N5O6
InChI Key
ZUQBAQVRAURMCL-DOMZBBRYSA-N
InChI
InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)/t12-,15+/m1/s1
IUPAC Name
(2S)-2-[(4-{2-[(6R)-4-hydroxy-2-imino-1H,2H,5H,6H,7H,8H-pyrido[2,3-d]pyrimidin-6-yl]ethyl}phenyl)formamido]pentanedioic acid
SMILES
[H][[email protected]@](CCC(O)=O)(NC(=O)C1=CC=C(CC[[email protected]@]2([H])CNC3=C(C2)C(O)=NC(=N)N3)C=C1)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UDihydrofolate reductaseNot AvailableEscherichia coli (strain K12)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lometrexol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Lometrexol.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Lometrexol.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lometrexol.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lometrexol.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Lometrexol.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lometrexol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lometrexol.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Lometrexol.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lometrexol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lometrexol.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Lometrexol.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Lometrexol.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Lometrexol.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Lometrexol.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Lometrexol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lometrexol.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Lometrexol.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Lometrexol.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lometrexol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
148138
PubChem Substance
347828954
ChemSpider
130593
BindingDB
22590
ChEMBL
CHEMBL34412
HET
DDF
PDB Entries
1dyj / 1rc4 / 1rx4 / 1rx5 / 1rx6 / 5cc9 / 5ccc

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusTreatmentDrug/Agent Toxicity by Tissue/Organ / Unspecified Adult Solid Tumor, Protocol Specific1
2Unknown StatusTreatmentLung Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP0.41ALOGPS
logP-3.1ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)-2.6ChemAxon
pKa (Strongest Basic)14.85ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area184.2 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity133.01 m3·mol-1ChemAxon
Polarizability44.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Glutamic acid and derivatives
Alternative Parents
Hippuric acids / N-acyl-alpha amino acids / Pyridopyrimidines / Benzoyl derivatives / Pyrimidones / Secondary alkylarylamines / Aminopyrimidines and derivatives / Pyridines and derivatives / Dicarboxylic acids and derivatives / Vinylogous amides
show 10 more
Substituents
Glutamic acid or derivatives / Hippuric acid or derivatives / Hippuric acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Pyridopyrimidine / Benzoic acid or derivatives / Benzamide / Benzoyl / Secondary aliphatic/aromatic amine
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyridopyrimidine, N-acyl-L-glutamic acid (CHEBI:41816)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Nadp binding
Specific Function
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
Gene Name
folA
Uniprot ID
P0ABQ4
Uniprot Name
Dihydrofolate reductase
Molecular Weight
17999.21 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on October 20, 2016 18:08 / Updated on November 09, 2017 05:12